$VRTX 3 SEC Filings

Filed On	Filing
22 Oct 2026	Form 3: Brennan Daniel J., Director No securities owned
10 Sep 2026	Form 3: van Grunsven Jasper, EVP, CP and NPPO No securities owned
03 Mar 2026	Form 3: Liu Joy, EVP and Chief Legal Officer Holds 23,703 shares of Common Stock
03 Feb 2026	Form 3: Bunnage Mark E., EVP, Chief Scientific Officer Holds 16,062 shares of Common Stock
02 Jul 2025	Form 3: McKechnie Duncan, EVP, Chief Commercial Officer Holds 16,130 shares of Common Stock
17 May 2024	Form 3: Schneider Jennifer, Director No securities owned
06 Dec 2023	Form 3: Thornberry Nancy, Director No securities owned
10 Oct 2023	Form 3: Lagarde Michel, Director No securities owned
05 Sep 2023	Form 3: Atkinson Edward Morrow Iii, EVP, Chief Technical Ops. Off. Holds 13,879 shares of Common Stock
21 Sep 2022	Form 3: Biller Jonathan, EVP and Chief Legal Officer No securities owned
18 May 2022	Form 3: Upadhyay Suketu, Director No securities owned
03 May 2021	Form 3: Ambrose Kristen, SVP & Chief Accounting Officer Holds 1,394 shares of Common Stock
08 Mar 2021	Form 3: Liu Joy, SVP, General Counsel Holds 13,394 shares of Common Stock
05 Feb 2021	Form 3: Sanna Bastiano, EVP, Cell & Genetic Therapies Holds 21,175 shares of Common Stock
05 Jun 2020	Form 3: Mckenzie Diana, Director Holds 207 shares of Common Stock
03 Oct 2019	Form 3: Tatsis Ourania, SVP, CRO Holds 3,500 shares of Common Stock
03 Oct 2019	Form 3: Bozic Carmen, EVP, GMDA Holds 2,097 shares of Common Stock
12 Apr 2019	Form 3: Wagner Charles F Jr, EVP and CFO No securities owned
22 Feb 2019	Form 3: Carney Lloyd, Director No securities owned
21 Dec 2018	Form 3: Vertex Pharmaceuticals (Europe) Ltd, 10% owner and 1 other · CRISPR Therapeutics AG Holds 5,250,000 shares of Common Shares

Comments